Regulation of mammalian Ste20 (Mst) kinases

Trends in Biochemical Sciences

Volumn 40, Issue 3, 2015, Pages 149-156

  Rawat, Sonali J ^a,b   Chernoff, Jonathan ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Dimerization; Serine threonine protein kinases; Signal transduction; Tumor suppressor

Indexed keywords

BINDING PROTEIN; MAMMALIAN STERILE TWENTY LIKE 1 KINASE; MAMMALIAN STERILE TWENTY LIKE 2 KINASE; PROTEIN KINASE; PROTEIN RASSF2; PROTEIN RASSF5; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; STK4 PROTEIN, HUMAN;

DIMERIZATION; DROSOPHILA; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; HETERODIMERIZATION; HIPPO PATHWAY; HOMODIMERIZATION; HUMAN; MAMMAL; NONHUMAN; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

MAMMALIA;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84923112266     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.01.001     Document Type: Review

References (72)

1. Zhao B., et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010, 24:862-874.
2. Zeng Q., Hong W. The emerging role of the Hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008, 13:188-192.
3. Creasy C.L., et al. The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain. J. Biol. Chem. 1996, 271:21049-21053.
4. Creasy C.L., Chernoff J. Cloning and characterization of a human protein kinase with homology to Ste20. J. Biol. Chem. 1995, 270:21695-21700.
5. Taylor L.K., et al. Newly identified stress-responsive protein kinases, Krs-1 and Krs-2. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:10099-10104.
6. Zhou D., et al. The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naive T cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20321-20326.
7. Zhou D., et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.
8. Song H., et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1431-1436.
9. Oh S., et al. Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Mol. Cell. Biol. 2009, 29:6309-6320.
10. Praskova M., et al. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr. Biol. 2008, 18:311-321.
11. Chan E.H., et al. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005, 24:2076-2086.
12. Hao Y., et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 2008, 283:5496-5509.
13. Zhao B., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21:2747-2761.
14. Zhao B., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1962-1971.
15. Zhang N., et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 2010, 19:27-38.
16. Yin F., et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154:1342-1355.
17. Nehme N.T., et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012, 119:3458-3468.
18. Katagiri K., et al. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat. Immunol. 2006, 7:919-928.
19. Nishikimi A., et al. Rab13 acts downstream of the kinase Mst1 to deliver the integrin LFA-1 to the cell surface for lymphocyte trafficking. Sci. Signal. 2014, 7:ra72.
20. Mou F., et al. The Mst1 and Mst2 kinases control activation of Rho family GTPases and thymic egress of mature thymocytes. J. Exp. Med. 2012, 209:741-759.
21. Lee K.K., et al. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J. Biol. Chem. 2001, 276:19276-19285.
22. Graves J.D., et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J. 1998, 17:2224-2234.
23. Ni L., et al. Structural basis for autoactivation of human Mst2 kinase and its regulation by RASSF5. Structure 2013, 21:1757-1768.
24. Anand R., et al. Biochemical analysis of MST1 kinase: elucidation of a C-terminal regulatory region. Biochemistry 2008, 47:6719-6726.
25. Hwang E., et al. Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9236-9241.
26. Jin Y., et al. Dimerization and cytoplasmic localization regulate Hippo kinase signaling activity in organ size control. J. Biol. Chem. 2012, 287:5784-5796.
27. Donninger H., et al. The RASSF1A tumor suppressor. J. Cell Sci. 2007, 120:3163-3172.
28. Dammann R., et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 2000, 25:315-319.
29. van der Weyden L., Adams D.J. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 2007, 1776:58-85.
30. Vos M.D., et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 2003, 278:28045-28051.
31. Eckfeld K., et al. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004, 64:8688-8693.
32. Allen N.P., et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007, 26:6203-6211.
33. Clark G.J., et al. RASSF family proteins. Mol. Biol. Int. 2012, 2012:938916.
34. Dallol A., et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004, 64:4112-4116.
35. Shivakumar L., et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 2002, 22:4309-4318.
36. Vos M.D., et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004, 64:4244-4250.
37. Vos M.D., et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 2000, 275:35669-35672.
38. Avruch J., et al. Protein kinases of the Hippo pathway: regulation and substrates. Semin. Cell Dev. Biol. 2012, 23:770-784.
39. Khokhlatchev A., et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 2002, 12:253-265.
40. Hwang E., et al. Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the Hippo signalling pathway. Acta Crystallogr. D: Biol. Crystallogr. 2014, 70:1944-1953.
41. Lu M.L., et al. UV irradiation-induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8977-8982.
42. Lehtinen M.K., et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006, 125:987-1001.
43. Watabe M., et al. Activation of MST/Krs and c-Jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis. J. Biol. Chem. 2000, 275:8766-8771.
44. Lee K.K., et al. Proteolytic activation of MST/Krs. STE20-related protein kinase, by caspase during apoptosis. Oncogene 1998, 16:3029-3037.
45. Kakeya H., et al. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis. Cancer Res. 1998, 58:4888-4894.
46. Glantschnig H., et al. Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J. Biol. Chem. 2002, 277:42987-42996.
47. Graves J.D., et al. Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J. Biol. Chem. 2001, 276:14909-14915.
48. Praskova M., et al. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 2004, 381:453-462.
49. Boggiano J.C., et al. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev. Cell 2011, 21:888-895.
50. Jang S.W., et al. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J. Biol. Chem. 2007, 282:30836-30844.
51. Yuan Z., et al. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120. J. Biol. Chem. 2010, 285:3815-3824.
52. Collak F.K., et al. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J. Biol. Chem. 2012, 287:23698-23709.
53. Qiao M., et al. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol. Cell 2010, 38:512-523.
54. Jung S., et al. PHLPP1 regulates contact inhibition by dephosphorylating Mst1 at the inhibitory site. Biochem. Biophys. Res. Commun. 2014, 443:1263-1269.
55. Romano D., et al. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 2010, 70:1195-1203.
56. Kim D., et al. Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS ONE 2010, 5:e9616.
57. Liu W., et al. Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS ONE 2012, 7:e36562.
58. Xiao L., et al. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J. Neurosci. 2011, 31:9611-9619.
59. O'Neill E., et al. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004, 306:2267-2270.
60. Oh H.J., et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006, 66:2562-2569.
61. Guo C., et al. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J. Biol. Chem. 2011, 286:6253-6261.
62. Matallanas D., et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 2007, 27:962-975.
63. Song H., et al. Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem. Biophys. Res. Commun. 2010, 391:969-973.
64. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 2000, 351:289-305.
65. Avruch J., et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 2001, 56:127-155.
66. Baccarini M. An old kinase on a new path: Raf and apoptosis. Cell Death Differ. 2002, 9:783-785.
67. O'Neill E., Kolch W. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 2005, 4:365-367.
68. Romano D., et al. Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling. Nat. Cell Biol. 2014, 16:673-684.
69. Kilili G.K., Kyriakis J.M. Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J. Biol. Chem. 2010, 285:15076-15087.
70. Chae J.S., et al. Thioredoxin-1 functions as a molecular switch regulating the oxidative stress-induced activation of MST1. Free Radic. Biol. Med. 2012, 53:2335-2343.
71. Morinaka A., et al. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. Oncogene 2011, 30:4208-4218.
72. Rawat S.J., et al. The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 protein. J. Biol. Chem. 2013, 288:8762-8771.